BrightSpire Capital heads into its July 29 earnings with short sellers quietly reducing exposure and the lending market offering no friction whatsoever to either side.
The short-selling story here is one of steady retreat. Short interest has fallen roughly 9% over the past month to 3.6% of free float — a level that is moderate for a small commercial mortgage REIT but no longer a primary tension. The week-on-week decline of nearly 4% continues a trend that has run since late May, when shorts peaked above 5.2 million shares. Cost to borrow has dropped sharply too, down 21% on the week to just 0.39% — essentially free to borrow. Availability backs that up: at nearly 1,192% of short interest, there are roughly twelve shares available for every one already shorted. That is well above the 52-week low of 287%, confirming the borrow market is loose and becoming looser. Positioning here looks more like an orderly cover than a squeeze, and the ORTEX short score has drifted lower across the past two weeks from 45.9 to 42.1 — a modest but consistent de-escalation.
Options tell a different story from the short book. The put/call ratio has eased to 13.6, below its 20-day mean of 16.1 — meaning the options market is actually less defensively positioned than usual, with relative call activity ticking up. The PCR z-score of -0.99 confirms the mild drift toward calls. Context matters here: BRSP's options market is thin, and PCR readings have ranged from 0.1 to 61.2 over the past year, so modest moves carry limited signal weight. What is notable is the shift from late May, when PCR was running above 19, toward the current 13-14 range — a quiet rotation that aligns with the short cover trend.
The Street is split but leaning cautiously constructive. BTIG upgraded the stock to Buy in late April with a $7.00 target. Jones Trading has reiterated its Buy at $6.50 three times in the past year without change. Barclays sits at the opposite pole, maintaining Underweight with a $6.00 target after raising it from $5.00 in February. All three targets sit above the current $5.54 price, implying 17-26% upside depending on the source, though the consensus is thin — just one formal outperform rating on the books. The price-to-book multiple of 0.76x has edged up 1.6% over the past month, a quiet re-rating that bulls would point to as evidence of improving sentiment. Forward earnings momentum scores are weak (13th-14th percentile on 90-day and 30-day EPS momentum), but the dividend score ranks in the 87th percentile — income investors are clearly still finding yield here despite the stock's 4% slide over the past month.
One ownership note worth flagging: CW Investment Advisers and Vanguard Capital Management both appear to have initiated fresh positions in Q1 2026, each adding their entire current holding in the quarter — 5.0% and 4.3% of shares respectively. That is a meaningful cluster of new institutional buying at a time when the stock was trading roughly in line with current levels. Nut Tree Capital, a credit-focused hedge fund, remains the largest disclosed holder at 8.4% with no change in Q1, suggesting patient accumulation rather than active rotation.
The next catalyst is earnings on July 29. The prior two prints produced a negative 4.4% next-day move each time. Shorts are covering into that window rather than building, and the borrow market offers no structural pressure either way — leaving the outcome squarely dependent on what management says about credit quality in the transitional loan book.
See the live data behind this article on ORTEX.
Open BRSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
